Skip to main content
Skip to main content
GMED logo

Globus Medical, Inc. (GMED)

$80.12 +$4.16 (+5.48%) |Exceptional · 97
Signals are mixed — the Council read leans STRONG BUY (88/100) while the AI fundamental score is 97/100 (grade A+); the two lenses disagree, so weigh the breakdown below. Strongest single signal: Izzy Englander bullish.
MCap: $10.81B| P/E Ratio: 18.5| Vol: 1.48M| Target: $107.17 (+33.8%)| 52-wk range: $51.79 – $101.40
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Globus Medical, Inc. (GMED) trades at $80.12 with AI Score 97/100 (Grade A+). Globus Medical, Inc. is a leading medical device company focused on innovative solutions for musculoskeletal disorders. Market cap: $10.81B, Sector: Healthcare.

Price live · AI analysis from May 10, 2026
Globus Medical, Inc. is a leading medical device company focused on innovative solutions for musculoskeletal disorders. Established in 2003, it offers a comprehensive range of spine and orthopedic products, positioning itself as a key player in the healthcare sector.

GMED stock analysis for 2026: Analysts have set a consensus price target of $107.17 for Globus Medical, Inc., suggesting 33.8% upside from the current price of $80.12. The AI MoonshotScore is 97/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.

Council Score · Weighted Average of 3 Disciplines
STRONG BUY 88/100 · A+

GMED: 6/7 perspectives are bullish. Dominant signal: Izzy Englander bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Ken Griffin
Bullish
Jim Simons
Neutral
Izzy Englander
Bullish
Seth Klarman
Bullish
Moon AI
Bullish
Council Score · 8 perspectives · See tabs for details →

Globus Medical, Inc. (GMED) Healthcare & Pipeline Overview

CEOKeith W. Pfeil
Employees5300
HeadquartersAudubon, PA, US
IPO Year2012

Globus Medical, Inc. specializes in developing advanced medical devices for musculoskeletal disorders, offering a diverse portfolio of spine and orthopedic solutions that leverage innovative technologies to enhance patient outcomes in the healthcare industry.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 10, 2026

What Is the Investment Thesis for GMED?

Globus Medical, Inc. presents a solid investment thesis driven by several key value drivers. The company boasts a market capitalization of $10.81B and a P/E ratio of 18.5, indicating strong profitability with a profit margin of 18.9% and a gross margin of 67.9%. Growth catalysts include the increasing prevalence of musculoskeletal disorders and the ongoing demand for innovative medical devices, particularly in the spine and orthopedic segments. The global orthopedic device market is projected to grow significantly, providing ample opportunities for expansion. Furthermore, the company's commitment to research and development positions it well to introduce new products that can capture market share. However, potential risks include regulatory challenges and competition from established players in the medical device industry. Overall, Globus Medical's robust product portfolio and strategic focus on innovation are expected to drive sustained growth in the coming years.

Based on FMP financials and quantitative analysis

GMED Key Highlights

  • Market capitalization of $10.81B reflects strong investor confidence and growth potential.
  • P/E ratio of 18.5 indicates solid profitability compared to industry peers.
  • Profit margin of 18.9% showcases operational efficiency and effective cost management.
  • Gross margin of 67.9% exceeds industry average, highlighting strong pricing power.
  • Employee base of 5,300 supports extensive operational capabilities and market reach.

Who Are GMED's Competitors?

GMED is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
ALGN Align Technology, Inc. $184.52 +1.67% $13.21B 88
PEN Penumbra, Inc. $318.57 +0.68% $12.53B 97
DVA DaVita Inc. $234.91 +3.02% $15.08B 88
MOH Molina Healthcare, Inc. $229.87 -1.15% $11.98B 80
HSIC Henry Schein, Inc. $86.43 +2.26% $9.85B 71
DCTH Delcath Systems, Inc. $13.61 +3.11% $469.84M 73
PYNKF Perimeter Medical Imaging AI, Inc. $0.19 +0.00% $17.66M 73
SSII SS Innovations International, Inc. $3.78 -4.06% $756.50M 72

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GMED's Key Strengths?

  • Innovative product offerings in the spine and orthopedic segments.
  • Strong financial performance with high gross and profit margins.
  • Established reputation and brand recognition in the medical device industry.
  • Robust research and development capabilities driving continuous innovation.

What Are GMED's Weaknesses?

  • Limited diversification outside the musculoskeletal device market.
  • Dependence on a few key product lines for revenue generation.
  • Potential challenges in navigating regulatory approval processes.
  • High competition in the medical device sector may impact market share.

What Could Drive GMED Stock Higher?

  • Launch of new spine products aimed at enhancing surgical outcomes and patient recovery.
  • Expansion of international operations to capture growing demand in emerging markets.
  • Continued investment in research and development to innovate and diversify product offerings.
  • Strategic partnerships aimed at enhancing distribution channels and market reach.
  • Focus on regulatory compliance to streamline approval processes for new products.

What Are the Key Risks for GMED?

  • Regulatory hurdles that could delay product launches and impact revenue.
  • Competitive pressures from established players in the medical device industry.
  • Economic fluctuations affecting healthcare spending and device adoption.
  • Supply chain disruptions that may impact product availability and delivery.

What Are the Growth Opportunities for GMED?

  • Growth opportunity 1: The global orthopedic device market is projected to grow significantly, reaching approximately $60 billion by 2027. This growth is driven by an aging population and an increase in musculoskeletal disorders, providing Globus Medical with opportunities to expand its product offerings and capture market share in both established and emerging markets.
  • Growth opportunity 2: The demand for motion preservation technologies is on the rise, with a growing preference for less invasive surgical options. Globus Medical's innovative solutions in dynamic stabilization and total disc replacement are well-positioned to capitalize on this trend, potentially increasing its market share in the spinal implant segment.
  • Growth opportunity 3: The interventional pain management market is expanding, with a focus on non-surgical treatment options for vertebral compression fractures. Globus Medical's product offerings in this area can benefit from the increasing demand for effective pain management solutions, contributing to revenue growth in the coming years.
  • Growth opportunity 4: The regenerative biologics market is gaining traction, with significant investments in research and development. Globus Medical's commitment to developing allografts and synthetic alternatives positions it to take advantage of this growing segment, potentially enhancing its product portfolio and revenue streams.
  • Growth opportunity 5: International expansion presents a significant growth opportunity for Globus Medical. As the company seeks to penetrate new markets, particularly in Asia-Pacific and Europe, it can leverage its innovative product offerings to meet the diverse needs of healthcare providers and patients globally.

What Opportunities Does GMED Have?

  • Expansion into international markets to increase revenue streams.
  • Growth in demand for minimally invasive surgical solutions.
  • Rising interest in regenerative medicine and biologic products.
  • Potential partnerships or acquisitions to enhance product portfolio.

What Threats Does GMED Face?

  • Intense competition from established medical device companies.
  • Regulatory changes that could impact product approval processes.
  • Economic downturns affecting healthcare spending.
  • Rapid technological advancements requiring continuous innovation.

What Are GMED's Competitive Advantages?

  • Strong focus on research and development leading to innovative product offerings.
  • Established brand reputation in the medical device industry enhances customer trust.
  • Comprehensive product portfolio addressing a wide range of musculoskeletal disorders.
  • Direct sales force strengthens relationships with healthcare providers and drives sales.
  • Commitment to quality and regulatory compliance builds competitive advantage.

What Does GMED Do?

Founded in 2003 and headquartered in Audubon, Pennsylvania, Globus Medical, Inc. has emerged as a prominent player in the medical device sector, dedicated to improving the quality of life for patients with musculoskeletal disorders. The company develops and commercializes a wide range of healthcare solutions, primarily focusing on spine products, orthopedic trauma, and joint reconstruction. Its product offerings include traditional fusion implants such as pedicle screw and rod systems, intervertebral spacers, and corpectomy devices designed to address various conditions including degenerative diseases, deformities, tumors, and trauma. Additionally, Globus Medical is at the forefront of motion preservation technologies, providing dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also offers interventional pain management solutions for vertebral compression fractures and regenerative biologic products, including allografts and synthetic alternatives. Globus Medical's orthopedic trauma solutions encompass fracture plates, compression screws, intramedullary nails, and external fixation systems, while its joint solutions include modular hip stems and knee arthroplasty implants. With a workforce of approximately 5,300 employees, Globus Medical continues to expand its footprint both domestically and internationally, striving to deliver innovative products that meet the evolving needs of healthcare providers and patients alike.

What Products and Services Does GMED Offer?

  • Develops and commercializes healthcare solutions for musculoskeletal disorders.
  • Offers a wide range of spine products, including fusion implants and motion preservation technologies.
  • Provides interventional pain management solutions for vertebral compression fractures.
  • Manufactures orthopedic trauma products, including fracture plates and intramedullary nails.
  • Distributes regenerative biologic products such as allografts and synthetic alternatives.
  • Focuses on joint reconstruction solutions, including hip and knee implants.

How Does GMED Make Money?

  • Generates revenue through the sale of medical devices for spine, orthopedic trauma, and joint reconstruction.
  • Utilizes a direct sales force and distribution partnerships to reach healthcare providers.
  • Invests in research and development to innovate and expand product offerings.
  • Maintains strong relationships with hospitals and surgical centers to drive product adoption.
  • Focuses on high-margin products to enhance profitability.

What Industry Does GMED Operate In?

The medical device industry is experiencing robust growth, driven by an aging population and the increasing prevalence of musculoskeletal disorders. The global orthopedic device market is expected to reach $60 billion by 2027, growing at a CAGR of approximately 5%. Globus Medical, Inc. operates in a highly competitive landscape, facing rivals such as Align Technology, Inc. (ALGN) and Penumbra, Inc. (PEN). The company's focus on innovation and comprehensive product offerings positions it favorably within this dynamic market, as healthcare providers seek advanced solutions to enhance patient outcomes.

Who Are GMED's Key Customers?

  • Hospitals and surgical centers that perform orthopedic and spinal surgeries.
  • Orthopedic surgeons and spine specialists who utilize medical devices in their practices.
  • Healthcare providers seeking innovative solutions for musculoskeletal disorders.
  • Patients requiring surgical interventions for spine and joint conditions.
  • Distributors and medical supply companies that sell devices to healthcare facilities.
AI Confidence: 73% Updated: May 10, 2026

How Globus Medical, Inc. Is Valued

Globus Medical, Inc. carries a market capitalization of $10.81B, placing it in the large-cap category. Relative to its peer group, GMED's quantitative score of 97/100 is above the peer average of 85/100.

Company Profile

Globus Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Audubon, US. The company is led by CEO Keith W. Pfeil. GMED has traded publicly since 2012.

ROE 13%Key Financial Metrics

Return on equity for Globus Medical, Inc. stands at 13.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.8%, showing how much profit it generates from its asset base. GMED trades at a trailing price-to-earnings ratio of 18.47, below the Healthcare sector average of ~23x. Its free cash flow yield is 5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.56 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.5%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 8/9Financial Health

Globus Medical, Inc.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 10.87 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Globus Medical, Inc. revenue of about $3.20B for fiscal 2026, with EPS near $4.74. The estimate reflects 10 contributing analysts.

Net buyingInsider Activity

Over the past six months, Globus Medical, Inc. insiders filed 28 SEC Form 4 transactions — 10 sales and 18 purchases. On net that is roughly 344K shares acquired (about $32.8M) — insiders putting money in tends to read as conviction.

GMED Financials

Fundamental Snapshot

Revenue Growth (FY)
+16.7%
Net Income Growth (FY)
+422.3%
EPS Growth (FY)
+423.7%
Free Cash Flow Growth (FY)
+45.3%
P/E (TTM)
18.2
Return on Equity (TTM)
+13.0%
Current Ratio
4.6
EV/EBITDA (TTM)
11.6

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Recent insider buying suggests confidence in the company's future, indicating that leadership believes in growth prospects.
  • Community sentiment has shifted positively, with discussions highlighting innovative product developments that could capture market share.
  • Increased focus on spinal surgery solutions aligns with rising demand in the healthcare sector, enhancing growth potential.
  • Analysts are noting improvements in operational efficiency, which could lead to better profit margins moving forward.

Bear Case

  • Concerns about regulatory challenges in the medical device industry have been prevalent, causing hesitation among investors.
  • Some community members express skepticism about the competitive landscape, fearing that larger players may overshadow GMED's innovations.
  • Recent market volatility has led to cautious sentiment, with investors wary of potential downturns affecting healthcare stocks.
  • The company's reliance on a few key products raises concerns about long-term sustainability if market dynamics shift unexpectedly.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026

GMED Latest News

GMED Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GMED.

Price Targets

Consensus target: $107.17

GMED MoonshotScore

97/100

What does this score mean?

The MoonshotScore rates GMED's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Keith W. Pfeil

CEO

Keith W. Pfeil has a distinguished career in the medical device industry, bringing extensive experience in leadership and operational management. He has held various roles in product development and strategic planning, contributing to the growth of Globus Medical since its inception in 2003. Pfeil is recognized for his commitment to innovation and excellence in healthcare solutions.

Track Record: Under Keith W. Pfeil's leadership, Globus Medical has achieved significant milestones, including the expansion of its product portfolio and entry into new markets. His strategic vision has driven the company's growth and positioned it as a leader in the medical device sector.

Globus Medical, Inc. Healthcare Stock: Key Questions Answered

What does Globus Medical, Inc. do?

Globus Medical, Inc. is a medical device company that develops and commercializes innovative solutions for patients with musculoskeletal disorders. The company offers a diverse range of products, including spine implants, orthopedic trauma devices, and biologics, aimed at improving patient outcomes and enhancing surgical procedures.

What do analysts say about GMED stock?

Analysts generally view GMED stock positively, citing its strong financial performance, robust product pipeline, and growth potential in the orthopedic device market. Key valuation metrics indicate that the company is well-positioned for future growth, although competitive pressures and regulatory challenges remain considerations for investors.

What are the main risks for GMED?

The main risks for Globus Medical, Inc. include regulatory hurdles that could delay product launches and impact revenue, as well as competitive pressures from established players in the medical device industry. Additionally, economic fluctuations may affect healthcare spending, and supply chain disruptions could impact product availability.

What are the key factors to evaluate for GMED?

Globus Medical, Inc. (GMED) holds an AI score of 97/100 (high). P/E: 18.5x vs the S&P 500's ~20-25x. Analysts target $107.17 (+34%). Not financial advice.

How frequently does GMED data refresh on this page?

GMED prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven GMED's recent stock price performance?

Globus Medical, Inc. (GMED) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings in the spine and orthopedic segments. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider GMED overvalued or undervalued right now?

Globus Medical, Inc. (GMED) trades at 18.5x earnings. Analysts target $107.17 (+34%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

What research should beginners do before buying GMED?

Before investing in Globus Medical, Inc. (GMED), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Data is based on current financial and operational metrics available as of May 10, 2026.
Data Sources

Popular Stocks